VistaGen Therapeutics (VTGN) Competitors $2.97 +0.24 (+8.79%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.02 +0.04 (+1.52%) As of 08/8/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. AURA, ARCT, ABEO, NBTX, RNAC, RCKT, CADL, AMRN, INBX, and NGNEShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Abeona Therapeutics (ABEO), Nanobiotix (NBTX), Cartesian Therapeutics (RNAC), Rocket Pharmaceuticals (RCKT), Candel Therapeutics (CADL), Amarin (AMRN), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Aura Biosciences Arcturus Therapeutics Abeona Therapeutics Nanobiotix Cartesian Therapeutics Rocket Pharmaceuticals Candel Therapeutics Amarin Inhibrx Biosciences Neurogene Aura Biosciences (NASDAQ:AURA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Is AURA or VTGN more profitable? Aura Biosciences has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Aura Biosciences' return on equity of -58.63% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -58.63% -49.74% VistaGen Therapeutics -6,777.08%-68.45%-59.95% Which has more volatility and risk, AURA or VTGN? Aura Biosciences has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Do insiders and institutionals believe in AURA or VTGN? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate AURA or VTGN? Aura Biosciences presently has a consensus target price of $22.00, indicating a potential upside of 223.53%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aura Biosciences is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, AURA or VTGN? VistaGen Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.90-3.58VistaGen Therapeutics$490K185.96-$51.42M-$1.78-1.67 Does the media prefer AURA or VTGN? In the previous week, VistaGen Therapeutics had 6 more articles in the media than Aura Biosciences. MarketBeat recorded 8 mentions for VistaGen Therapeutics and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.84 beat VistaGen Therapeutics' score of 0.12 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAura Biosciences beats VistaGen Therapeutics on 11 of the 16 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.12M$2.99B$5.47B$9.71BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-1.6717.3230.1024.70Price / Sales185.96326.67458.19100.35Price / CashN/A40.7324.8428.01Price / Book1.228.888.525.76Net Income-$51.42M-$54.75M$3.27B$267.05M7 Day Performance2.06%-2.07%4.65%3.13%1 Month Performance24.79%1.81%0.96%1.27%1 Year Performance-12.90%8.71%36.43%22.83% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics1.2924 of 5 stars$2.97+8.8%N/A-12.9%$91.12M$490K-1.6740Earnings ReportUpcoming EarningsGap UpAURAAura Biosciences1.9426 of 5 stars$6.61-1.9%$22.00+232.8%-18.1%$338.81MN/A-3.4850Positive NewsUpcoming EarningsARCTArcturus Therapeutics2.6992 of 5 stars$12.20-0.8%$54.00+342.6%-34.1%$333.58M$152.31M-4.82180News CoverageAnalyst UpgradeABEOAbeona Therapeutics3.774 of 5 stars$6.42-1.1%$19.25+199.8%+41.6%$332.01M$3.50M-5.0690NBTXNanobiotix0.3028 of 5 stars$6.80flat$8.00+17.6%+51.2%$320.51M$39.18M0.00100Gap UpHigh Trading VolumeRNACCartesian Therapeutics1.9172 of 5 stars$12.48+1.2%$40.00+220.5%-21.2%$320.02M$38.91M-0.2464Positive NewsEarnings ReportRCKTRocket Pharmaceuticals4.8424 of 5 stars$3.07+2.7%$17.87+482.0%-85.0%$319.29MN/A-1.17240Trending NewsEarnings ReportAnalyst ForecastCADLCandel Therapeutics2.4936 of 5 stars$6.31+0.3%$22.00+248.7%+5.4%$315.15MN/A-4.7160Upcoming EarningsAMRNAmarin0.5975 of 5 stars$15.38+1.5%$12.00-22.0%+19.4%$313.92M$228.61M-4.19360INBXInhibrx Biosciences0.9543 of 5 stars$21.80+0.9%N/A+90.8%$312.68M$200K0.19166Upcoming EarningsNGNENeurogene2.9514 of 5 stars$21.72-0.3%$46.17+112.6%-40.4%$310.63M$925K-4.9990Gap Up Related Companies and Tools Related Companies AURA Alternatives ARCT Alternatives ABEO Alternatives NBTX Alternatives RNAC Alternatives RCKT Alternatives CADL Alternatives AMRN Alternatives INBX Alternatives NGNE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale